Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Metachol distribution agreement

Aug. 23, 1996

Eisai's squalene synthase inhibitor and prodrug

Aug. 23, 1996

Yamanouchi and PT CarbaPharma describe cathepsin L inhibitor

Aug. 23, 1996

Indian hedgehog molecule's role in cartilage and bone development

Aug. 23, 1996

Osteocalcin study findings reported

Aug. 23, 1996

Aredia earns U.S. approval for new indication

Aug. 23, 1996

Conceptus reports clinical advances with S/TOP system

Aug. 16, 1996

Zonagen initiates pivotal trials of Vasomax

Aug. 16, 1996

Andropatch marketed in U.K.

Aug. 16, 1996

BASF to manufacture Ares-Serono's hGH

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...